QS Investors’s Travere Therapeutics TVTX Stock Holding History

QS Investors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-337	Closed	-$7K	–	1533
2020 Q2	$7K	Hold	337	–	–	﹤0.01%	1591
2020 Q1	$5K	Buy	337 +200	+146%	+$3.01K	﹤0.01%	1608
2019 Q4	$2K	Hold	137	–	–	﹤0.01%	1616
2019 Q3	$2K	Hold	137	–	–	﹤0.01%	1627
2019 Q2	$3K	Hold	137	–	–	﹤0.01%	1618
2019 Q1	$4K	Hold	137	–	–	﹤0.01%	1614
2018 Q4	$4K	Hold	137	–	–	﹤0.01%	1605
2018 Q3	$4K	Hold	137	–	–	﹤0.01%	1624
2018 Q2	$4K	Buy	137 +10	+8%	+$266	﹤0.01%	1648
2018 Q1	$3K	Hold	127	–	–	﹤0.01%	1658
2017 Q4	$3K	Buy	+127	New	+$2.9K	﹤0.01%	1658

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

QS Investors's TVTX Position: Q3 2020 in Review

QS Investors sold out of Travere Therapeutics (TVTX) in Q3 2020, closing a stake of 337 shares — an estimated $7K sold.

QS Investors first reported a position in TVTX in Q4 2017 and held it in 11 quarters. The position peaked at $7K in Q2 2020. 134 funds tracked by Wall St. Rank hold TVTX as of Q3 2020.

QS Investors reported no remaining Travere Therapeutics position as of Q3 2020 after selling out during the quarter.
QS Investors sold 337 Travere Therapeutics shares in Q3 2020, an estimated $7K.
QS Investors first reported a position in Travere Therapeutics in Q4 2017 and held it in 11 quarters.
QS Investors's Travere Therapeutics position peaked at $7K in Q2 2020.
134 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2020.

Based on QS Investors's 13F filing for Q3 2020, filed 12 Nov 2020.